Activity Info

Join leading oncologists for an expert roundtable that goes beyond the basics. In this dynamic, case-focused discussion, clinicians will sharpen their ability to distinguish uveal vs. cutaneous melanoma, confidently apply guideline-driven treatments for mUM, and understand why HLA A*02:01 testing is shaping therapeutic decisions. Discover the science behind bispecific TCR therapy, unpack real-world clinical trial data, and learn how these advances translate into better outcomes—especially in the VA care setting.